METAP2 and neoplasm: Inhibition of the enzymatic activity of MetAP2 leads to a variety of changes in protein functionality impacting both tumor growth and proliferation, as well as, by acting directly on endothelial cells, inhibiting angiogenesis in a vascular endothelial growth factor (VEGF)-independent manner.